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Background: In HIV-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on 
antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We 
assessed the prevalence and outcomes of poor immune response (PIR) in children on suppressive 
ART. 
Methods: Sixteen cohorts from the European Pregnancy and Paediatric HIV Cohort Collaboration 
(EPPICC) contributed data. Children aged<18 years at ART initiation, with sustained viral suppression 
(VS) (≤400copies/mL) for ≥1 year were included. The prevalence of PIR (defined as WHO 
advanced/severe immunosuppression for age: CD4%<30% in children aged<12 months, CD4%<25% 
in 12-35 months, CD4%<20% in 36-59 months; CD4%<15%/CD4<350 cells/mm3 in ≥5-years) at 1 year 
of VS was described.  Factors associated with PIR were assessed using logistic regression.  Rates of 
AIDS or death on suppressive ART were calculated by PIR status. 
Results: Of 2318 children included, median age was 6.4 [IQR, 2.1, 10.4] years and 68% had 
advanced/severe immunosuppression at ART initiation. At 1 year of VS, 12% had PIR. In multivariable 
analysis, PIR was associated with older age and worse immunological stage at ART start, hepatitis-B 
coinfection and residing in Thailand (all p≤0.03). Rates of AIDS/death (95% CI) per 100,000 person-
years were 1052 (547, 2022) among PIR versus 261 (166, 409) among immune responders; rate ratio 
of 4.04 (1.83, 8.92), p<0.001.   
Conclusions: One in eight children in our cohort experienced PIR despite sustained viral suppression.  
While the overall rate of AIDS/death was low, children with PIR had four-fold increase in risk of 







Antiretroviral treatment (ART) has led to a dramatic reduction in AIDS and mortality in children and 
adults living with HIV[1-3].  Adults on treatment who achieve immune recovery with CD4 counts 
over500 cells/mm3 have improved life expectancy, approaching that of the general population[4, 5]. 
However, some patients experience discordant treatment responses, with poor immune response 
(PIR) despite sustained viral suppression (VS).  
A systematic review of 20 adult studies on discordant treatment response reported wide variations 
in the definitions of PIR; nonetheless, most studies were consistent in their findings of a 2-3 fold 
increase in risk of mortality among adults with PIR compared to immune responders [6].  The 
definitions of PIR ranged  from a CD4 count increase of <50 cells/mm3 at 6 to 12 months after start 
of suppressive ART, to failure to reach absolute CD4 values of ≥200 to ≥500 cells/mm3 at 6 to 60 
months of suppressive ART (defined as viral load (VL) <50 to <1000 copies/mL)[6].  The prevalence of 
PIR ranged from 11% to 45%, and older age and lower CD4 at ART start were commonly associated 
with PIR[7, 8].  Fewer studies assessed the risk of progression to AIDS or death as a composite 
outcome; some observed an elevated risk among adults with PIR[9], while others did not[6, 7].   
There are scarce comparable data on PIR in children. Numerous studies have shown that most 
children achieve good immune response to ART, although those who initiate ART at older ages or 
with advanced immunosuppression were less likely to achieve immune recovery[10-13].  However, 
these studies included all children on ART irrespective of viral suppression status so it is unclear if 
the blunted immune recovery was partly due to non-suppressive ART[14, 15], rather than intrinsic 
poor immune response.   
In this study, we assessed the prevalence of PIR among children who achieved sustained viral 
suppression on ART, the associated factors and clinical outcomes within the European Pregnancy 






Sixteen paediatric observational cohorts from 15 middle- and high-income countries across Europe 
and Thailand in EPPICC contributed data.  Patient level clinical data were pooled electronically using 
a modified HICDEP protocol (www.hicdep.org), as described elsewhere[16].  
Inclusion criteria for this analysis were: (i) age <18 years at initiation of combination ART (defined as 
≥3 drugs from ≥2 classes (excluding unboosted protease inhibitors (PI)), or ≥3 nucleoside reverse 
transcriptase inhibitors (NRTI) regimen containing abacavir); (ii) ≥1 CD4 and viral load (VL) 
measurement on ART; (iii) achieved VS (defined as VL≤400 copies/mL) within 1 year after ART start 
(or within 18 months for infants aged<12 months at ART start) and maintained VS for ≥1 year.  
Patients with documented sexual mode of transmission (n=17) were excluded as they were much 
older at HIV diagnosis than children with perinatal HIV (median age at HIV diagnosis of 15.6 years 
[interquartile range (IQR), 14.4, 16.7] versus 6.0 [1.6, 10.6], respectively).   
Follow-up was from ART initiation until the earliest of death, loss to follow up (LTFU), 21st birthday, 
or last visit in paediatric care, with data through to 1st October 2016.  All cohorts had routine CD4 
and VL monitoring, at least annually.  AIDS defining opportunistic infections and illnesses were based 
on the US Centers for Disease Control and Prevention 2014[17] definition..  All cohorts received 
local/national ethics approval. 
Definitions of viral suppression and poor immune response 
The period of VS started at the midpoint between the first VL≤400 copies/mL and the previous 
VL>400 copies/mL (or at ART initiation if later).  Patients were censored at the end of VS (at last 
VL≤400 copies/mL), defined as the earliest of the following: (i) viral rebound (two consecutive 




measurements of >15 months (censored at last VL before gap); (iii) ART interruption (defined as 
stopping all drugs for >14 days); (iv) death or last follow-up in paediatric care. In sensitivity analyses, 
we censored patients at start of a gap between VL measurements of >12 months .  
PIR was defined as World Health Organization (WHO) advanced or severe immunological stage for 
age at 1 year of VS: CD4<30% for age <12 months; CD4<25% for 12-35 months; CD4<20% for 35-59 
months; CD4<15% or <350 cells/mm3 for ≥5 years[18].  Children with CD4% or cell counts above 
these thresholds (WHO none or mild stage) were considered ‘immune responders’. 
Statistical methods 
Among patients with WHO advanced or severe immunosuppression at ART initiation, time to 
immune recovery was estimated using Kaplan-Meier survival functions. 
Among patients with CD4 measurements available at 1, 2 and 3 years of sustained VS (±3 month 
window), the prevalence of PIR was assessed at each time point.  
Factors associated with PIR at 1 year of VS were assessed using logistic regression. Potential risk 
factors were characteristics at ART initiation: sex, mode of HIV infection (perinatal vs 
other/unknown), born abroad (vs in country of cohort), year of birth (<2000 vs ≥2000), age, WHO 
immunological stage, viral load, AIDS diagnosis, BMI-for-age z-score (based on WHO reference 
standards[19]), , tuberculosis disease prior to or soon after ART start (± 6 months), cytomegalovirus 
(CMV) disease related AIDS event prior to ART start, initial ART regimen, calendar year of ART 
initiation, ever diagnosed with hepatitis B (HBV) and C (HCV) co-infection, and geographic region 
(UK/Ireland, Eastern Europe (Russia/Ukraine), Western and Central Europe, and Thailand). All factors 
were considered in the multivariable model, and the final model was determined using backwards 
selection (exit probability=0.05).  The missing indicator method was used for variables with missing 
data. For HBV and HCV co-infection, CMV, and tuberculosis disease, the odds ratios of the missing 




included in the final model were considered. This analysis was repeated to explore factors associated 
with PIR at 2 years of VS.  
AIDS and death on suppressive ART 
We assessed the rate of clinical events (new/recurrent AIDS event or death) while on suppressive 
therapy, by PIR status at 1 year of VS.  Children entered at risk at 1 year of VS and were censored at 
first AIDS event or death or at the end of VS.   
To explore the management of PIR, we assessed the rate of treatment changes (defined as a change 
in main drug class, from non-nucleoside reverse transcriptase inhibitors (NNRTI) to PI-based 
regimen, or vice versa, or addition of a new drug class) during VS.  We also described the median 
change in height and BMI-for-age z-scores[19] between ART initiation and 1 year of VS by PIR status.   
All statistical analyses were performed using Stata version 14.2 (Stata Corporation, College Station, 





Of 3,395 children with over one year of follow-up after ART start, 2,318 (68%) had sustained VS for 
≥1 year and were included in this analysis (Figure 1). The largest proportion were from the 
UK/Ireland (37%), followed by Western/Central Europe (32%), Thailand (17%) and Eastern Europe 
(14%) (Table 1). Half were female, and 91% had perinatal HIV.  At ART initiation, median [IQR] age 
was 6.4 years [2.1, 10.4], median CD4 was 22% [14, 33] among <5 years and 256 cells/mm3 [94, 417] 
among ≥5 years.  Overall, 68% were advanced or severely immunocompromised and 19% had a prior 
AIDS diagnosis at ART start. One-third initiated on PI-based regimens (87% on lopinavir), 36% on 
efavirenz -, and 28% on nevirapine-based regimens. The median duration of follow-up after ART 
start was 6.8 years [4.0, 9.7], during which 23 (1%) children died, 271 (12%) were LTFU, 660 (28%) 
transferred to other clinics/adult care, and 170 (7%) were censored at their 21st birthday. 
Immune response 
At 1 year of VS, 83% of children (n=1,926/2,318) had a CD4 measurement available, of whom 88% 
had good immune status, an increase from 32% at ART start.  Among patients with advanced/severe 
immune suppression at ART start, the time to immune recovery was rapid for the vast majority: 72% 
(95% CI, 70, 74) reached WHO none/mild stage by 1 year after ART start (Figure 2).    
Overall, 12% (237/1,926) of children had PIR at 1 year of VS; they were more likely to be from 
Thailand, were older, with poorer immune status, with a higher proportion severely stunted and 
wasted at ART start as compared to immune responders (Table 2, all p<0.001).  However, one-fifth 
of children with PIR were not severely immunocompromised at ART start.  The median CD4 at 1 year 
of VS was 21% [16, 23] among <5 years and 299 cells/mm3 [246, 336] in ≥5 years among children 
with PIR compared to 36% [31, 42] and 690 cells/mm3 [537, 915] among immune responders, 
respectively.   Among children aged≥5 years, the median increase in CD4 from ART start to 1 year of 




Children with missing CD4 at 1 year of VS (n=392) were more likely to be from Eastern European 
cohorts (41% missing among children from Eastern Europe versus 13% in other regions, p<0.001), 
initiated ART at younger ages (median 3.3 years [0.8, 8.5] versus 6.9 years [2.6, 10.6], p<0.001) with 
better immune status (16% WHO stage none/mild versus 11%, p=0.009) compared to children with 
CD4 measurements (data not shown). 
The number of children with sustained VS for two (n=1873) and three (n=1509) years after ART start 
declined over time. Among those with CD4 measurements available, the prevalence of PIR fell to 7% 
(n=104/1594) and 3% (n=46/1332), respectively.   
Factors associated with PIR  
In multivariable analyses, factors associated with PIR at 1 year of VS were: older age and worse 
immune stage at ART start, HBV coinfection and being in the Thai cohort (Table 2). Children aged 5-
10 years at ART start had 1.8 times higher odds of PIR compared to <5 years, with the odds 
increasing with each older age group (p<0.001).  The odds of PIR increased with worse levels of 
immunodeficiency at ART start and in those with missing baseline CD4 (p<0.001),   Children in the 
Thai cohort had a two-fold increased odds of PIR (adjusted odds ratio aOR 2.16, 95% CI, 1.49, 3.13) 
compared to UK/Ireland, while there was no significant difference within the European regions. HBV 
co-infection was also associated with an increase in risk of PIR (aOR 2.14, 95% CI, 1.08, 4.25, 
p=0.029). After adjustment for these factors, no other factors were associated and no significant 
interactions were found.  
Factors associated with PIR at 2 years of VS were broadly similar with older age and worse immune 
stage at ART start being the strongest predictors, while the association with HBV coinfection 
weakened (p=0.068), and effect of the Thai cohort was no longer present  (Supplementary table S1) 




Overall, there were seven deaths and 21 new AIDS events on suppressive therapy, of which four 
(57%) deaths and five (23%) AIDS events were among children with PIR at 1 year of VS corresponding 
to 3.8% (9/237) AIDS/death among those with PIR versus 1.1% (19/1689) among immune 
responders. The majority of events were infections-related (Tables 3 and 4). The median time from 
ART start to first event was 1.4 years [IQR, 1.3, 1.7] among children with PIR versus 3.0 years [IQR, 
1.6, 5.4] in immune responders (p=0.121).  The rate of AIDS/death (95% CI) during VS was 1,052 
(547, 2,022) per 100,000 person-years (PY) among PIR versus 261 (166, 409) among immune 
responders, a rate ratio of 4.04 (1.83, 8.92, p<0.001) (Supplementary table S2).    
There was no difference in the proportion or rate of switch to alternative treatment regimens by 
immune response status (8.4% in PIR versus 9.1% in immune responders, p=0.733; 1.88 per 100PY 
(1.21, 2.92) versus 1.78 (1.52, 2.09), respectively, p=0.821).  The median increase in BMI-for-age z-
score from ART start to 1 year of VS among PIR was comparable at 0.3 [IQR, -0.3, 1.1] versus 0.2 [IQR 
-0.3, 0.9], respectively (p=0.120), while the median increase in height-for-age z-score was lower 
among PIR at 0.1 [IQR, -0.2, 0.4] versus 0.2 [IQR, -0.1, 0.6] respectively (p<0.001) (Supplementary 
Table S3). 
In sensitivity analyses where we censored patients with >12 month gap in VL measurements, the 
findings were consistent with the main analyses with a 12% prevalence of PIR at 1-year of VS , similar 
associated factors and elevated risk of AIDS/death among PIR (data not shown).   
Discussion:  
To our knowledge this is one of the first studies to estimate the prevalence and clinical outcomes of 
PIR among children on suppressive ART in settings with routine CD4 and VL monitoring. In our 
cohort, 12% of children had PIR at 1 year of VS and these children had a four-fold increased risk of 




Our prevalence of PIR was relatively low compared to adult studies, which may be partly due to the  
differences in inclusion criteria and definitions of PIR[6].  One large study in adults in Europe 
reported 15% with PIR at 3 years of VS, where PIR was defined as severe immunosuppression 
(CD4<200 cells/ mm3) and was restricted to patients severely immunocompromised at start of the 
virally suppressed period[20].  In contrast, we focused on PIR at 1 year of VS, defined as advanced or 
severe immunosuppression for age, and included all children irrespective of their baseline immune 
status, and one-fifth of children with PIR were not severely immunocompromised at ART start.  
Encouragingly, the 12% prevalence of PIR at 1 year of VS declined to 3% among those virologically 
suppressed for 3 years. This probably reflects the increased thymic output and capacity for immune 
reconstitution in children as compared to adults[21, 22].  
The overall rate of AIDS or death in children on suppressive ART in our cohort was low, including 
among children with PIR, which highlights the significant benefit of treatment for these children.  
However, children with PIR had a disproportionately high burden of events, accounting for over half 
of the deaths and a quarter of AIDS events.   
It is difficult to directly compare with previous paediatric studies on PIR as they were not restricted 
to children on suppressive ART.  However, the main factors associated with PIR were consistent with 
our study, being older age and poorer immune stage at ART start[10, 12, 13]. This highlights the 
critical importance of early HIV diagnosis and initiation of ART in infancy and prior to disease 
progression to minimise the risk of poor immune recovery[23].  In our analysis, being in the Thai 
cohort was associated with increased odds of PIR as compared to the UK/Ireland. Children in 
Thailand were more likely to be at advanced disease stage at ART start, and there may be 
unmeasured confounding and/or higher background risk of infectious diseases[24].  HBV coinfection 
was also associated with increased in risk of PIR.  Poor immune recovery among HIV-HBV co-infected 
patients has been reported in adult studies, which may be due to systemic inflammation related to 




of VS found weakened association with HBV co-infection and the Thai cohort effect was no longer 
present, although this was based on a smaller sample size.  
 
Our findings highlight three key issues. First, timely ART initiation in early life, prior to 
immunosuppression as per WHO recommendations was highly protective of PIR [23].  However on 
the global level, only half of children living with HIV have access to ART[1], and the majority of 
children in sub-Saharan Africa still start ART at advanced or severe immunosuppression and 
therefore are at increased risk of PIR[28].  The expansion of targeted services for early HIV diagnosis 
including birth testing in high prevalence settings has resulted in earlier initiation of ART in 
infancy[29]. 
Second, after adjusting for patient characteristics, children in Thailand were at increased risk of PIR 
at 1 year of VS compared to UK/Ireland.  The clinical outcomes of PIR among children in low and 
middle-income countries is largely unknown; they may face a similar or higher burden of disease 
progression and death than that observed in our cohorts.  Currently there are no clear 
recommendations to reduce the excess morbidity and mortality associated with PIR[6]. The recent 
REALITY trial in sub-Saharan Africa reported significant reduction in early deaths among children and 
adults initiating ART with very severe immunodeficiency (CD4<100 cells/mm3), when provided with 
an enhanced antimicrobial prophylaxis package as compared to standard prophylaxis to prevent 
opportunistic infections[30].  We did not have data on use of antimicrobial prophylaxis in this cohort 
and could not explore this question further.   
Third, our findings highlight the potential importance of CD4 monitoring alongside the global scale 
up of VL monitoring[31], in the assessment of baseline immune status and  early response to ART, to 
identify patients with PIR who may require closer follow-up and to inform decisions on 




patients on suppressive therapy with no or mild immunosuppression offers limited benefits in 
settings with routine VL monitoring due to the low risk of CD4 decline in this populationthese 
recommendations do not extend to patients with PIR despite VS[34]. Furthermore, there are limited 
evidence on when to reduce or stop CD4 monitoring in children, this is identified as a key area for 
research needed to inform future policies[32]. Similarly, the optimal clinical management of PIR in 
children in both resource-rich and resource-limited settings remains unclear and is a research gap in 
paediatric HIV infection.   
While our study benefits from a large sample size of children with long duration of follow-up of over 
6 years, there are important study limitations. First, 392 (17%) children had missing CD4 at 1 year of 
VS which may have led to under- or over-estimation of PIR. This includes 16 children aged≥5 years 
with CD4%>15% but no CD4 cell count measurement to confirm their immune status for age.   
Second, our clinical outcome was limited to AIDS or death; we did not have complete reporting of 
CDC B events or serious non-AIDS events, which have been associated with PIR in some adult 
studies[36].   
Conclusion:  
One in eight children on suppressive antiretroviral therapy had PIR.  While the overall rate of AIDS 
and death in this cohort was low, children with PIR had a disproportionately high risk ofdisease 
progression and death.  Optimal management of PIR remains unclear but should include 
continuation of antimicrobial prophylaxis, investigation of subclinical opportunistic and chronic 
infections. The key finding is that treatment at a young age and prior to severe immunosuppression  
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COORDINATING CENTRE  
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Poland: Polish paediatric cohort: Head of the team: Prof Magdalena Marczyńska, MD, 
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Table 1: Characteristics of children with sustained viral suppression for >1 year, by immune response 
status 
 
All children with 
VS ≥1 year* 
(n=2318) 
Immune 
responders at 1 




1 year of VS 
(n=237) 
n (%) or median (IQR) 
Demographics 
Sex, male  1084 (47) 783 (46) 121 (51) 
Age at HIV diagnosis (years) (n=2090, 1546, 218) 3.8 (1.0, 8.0) 4.0 (1.1, 7.9) 7.6 (3.3, 11.0) 
Born abroad (n=2248, 1641, 222) 810 (36) 614 (37) 80 (36) 
Year of birth <2000 1101 (48) 794 (47) 169 (71) 
Mode of HIV infection 
Perinatal 2119 (91) 1555 (92) 195 (82) 
Blood products 88 (4) 58 (3) 22 (9) 
Other 5 (0.2) 3 (0.2) 0 
Unknown 106 (5) 73 (4) 20 (8) 
Region  
UK/Ireland 849 (37) 693 (41) 83 (35) 
Eastern Europe 332 (14) 183 (11) 12 (5) 
Western/Central Europe 751 (32) 546 (32) 66 (28) 
Thailand 386 (17) 267 (16) 76 (32) 
Characteristics at start of ART  
Age (years) 6.4 (2.1, 10.4) 6.5 (2.4, 10.3) 9.7 (6.1, 13.5) 
CD4% among <5 years (n=740/970, 582/688, 36/46) 22 (14, 33) 22 (14, 33) 16 (8, 22) 
CD4 count (cells/µl) among those ≥5 years 
(n=1180/1348, 887/1001, 173/191) 
256 (94, 417) 287 (130, 446) 112 (26, 220) 
WHO immunological 
stage (n=1931, 1473, 
210) 
None 396 (21) 327 (22) 4 (2) 
Mild 228 (12) 190 (13) 5 (2) 
Advanced 305 (16) 238 (16) 33 (16) 
Severe 1002 (52) 718 (49) 168 (80) 
Viral load (log10 copies/ml) (n=1862, 1390, 191) 5.0 (4.4, 5.5) 5.0 (4.4, 5.5) 4.9 (4.3, 5.3) 
AIDS diagnosis (n=2304, 1679, 236) 442 (19) 312 (19) 57 (24) 
Hepatitis B coinfection (n=2049, 1494, 216) 64 (3) 43 (3) 14 (6) 
Hepatitis C coinfection (n=1944, 1424, 203) 69 (4) 47 (3) 5 (2) 
Tuberculosis disease 56 (2) 38 (2) 11 (5) 
CMV coinfection 38 (2) 27 (2) 2 (1) 
BMI-for-age z-score <-3 (n=1509, 1152, 173) 74 (5) 45 (4) 17 (10) 
Height-for-age z-score <-3 (n=1511, 1153, 173) 195 (13) 135 (12) 31 (18) 
Initial regimen 
Boosted PI+NRTI 768 (33) 538 (32) 55 (23) 
EFV+≥2NRTI 833 (36) 626 (37) 108 (46) 
NVP+≥2NRTI 641 (28) 466 (28) 68 (29) 
Other 76 (3) 59 (3) 6 (3) 
Calendar year at ART 
initiation 
<2004 550 (24) 399 (24) 61 (26) 
2004 - 2007 805 (35) 583 (35) 109 (46) 
≥2008 963 (42) 707 (42) 67 (28) 
* Includes 392 children with missing CD4 at 1 year of viral suppression.   
ART=antiretroviral therapy; BMI=body mass index; CMV=cytomegalovirus; EFV=efavirenz; 
IQR=interquartile range; NNRTI=non-nucleoside reverse transcriptase inhibitors; NRTI=nucleoside 
reverse transcriptase inhibitors; NVP=nevirapine; PI=protease inhibitor; VS=viral suppression; 
WHO=World Health Organization 
  
7DEOH &OLFNKHUHWRDFFHVVGRZQORDG7DEOH(33,&&7$%/(6&/($1GRF[
Table 2: Predictors of Poor immune response at 1 year of viral suppression 




OR 95% CI p-value aOR 95% CI p-value 
Demographics 
Sex 
Female 116/1022 (11) 0.83 0.63, 1.09 
0.175 - 
Male 121/904 (13) 1.00 - 
Place of birth 
Country of 
cohort 
142/1169 (12) 1.00 - 
0.021 - 
Abroad  80/694 (12) 0.94 0.70, 1.26 
Unknown 15/63 (24) 2.26 1.23, 4.14 
Year of birth 
<2000 169/963 (18) 1.00 - 
<0.001 - 
≥2000 68/963 (7) 0.36 0.27, 0.48 
Mode of HIV 
infection 
Perinatal 195/1750 (11) 1.00 - 
<0.001 - 
Other/ Unknown 42/176 (24) 2.50 1.71, 3.64 
Region of 
cohort 




Eastern Europe 12/195 (6) 0.55 0.29, 1.02 0.92 0.48, 1.78 
Western/Central 
Europe 
66/612 (11) 1.01 0.72, 1.42 1.19 0.82, 1.72 
Thailand 76/343 (22) 2.38 1.69, 3.34 2.16 1.49, 3.13 
Characteristics at start of ART 
Age (years) 




5 - <10 79/624 (13) 2.17 1.48, 3.17 1.82 1.22, 2.71 
10 - <15 78/483 (16) 2.88 1.96, 4.23 2.39 1.60, 3.55 








Mild 5/256 (3) 2.15 0.57, 8.11 1.98 0.52, 7.51 
Advanced 33/271 (12) 11.34 3.96, 32.43 9.35 3.23, 27.06 
Severe 168/886 (19) 19.12 7.04, 52.00 13.96 5.08, 38.37 
Unknown 27/243 (11) 10.22 3.53, 29.61 9.23 3.15, 27.01 
Viral load 
(copies/mL) 
>100,000 79/753 (11) 1.00 - 
0.153 - ≤100,000 112/828 (14) 1.33 0.98, 1.81 
Unknown 46/345 (13) 1.31 0.89, 1.94 
AIDS 
diagnosis  
Yes 57/369 (15) 1.40 1.01, 1.93 
0.042 - 
No 180/1557 (12) 1.00 - 
Hepatitis B 
co-infection 
Yes 14/57 (25) 2.40 1.29, 4.46 
0.006 
2.14 1.08, 4.25 
0.029 
No/Unknown 223/1869 (12) 1.00 - 1.00 - 
Hepatitis C 
co-infection 
Yes 5/52 (10) 0.75 0.30, 1.91 
0.551 - 
No/Unknown 232/1874 (12) 1.00 - 
Tuberculosis 
disease 
Yes 11/49 (22) 2.11 1.07, 4.20 
0.032 - 
No 226/1877 (12) 1.00 - 
CMV co-
infection 
Yes 2/29 (7) 0.52 0.12, 2.22 
0.380 - 
No 235/1897 (12) 1.00 - 
BMI-for-age 
z-score 
>0 68/634 (11) 1.00 - 
0.001 - 
-3 to 0 86/629 (14) 1.35 0.97, 1.90 
<-3 17/62 (27) 3.14 1.71, 5.80 
Unknown 64/601 (11) 0.99 0.69, 1.42 
Initial 
regimen 
Boosted PI+NRTI 55/593 (9) 1.00 - 
0.023 - 
EFV+≥2NRTI 108/734 (15) 1.68 1.20, 2.38 
NVP+≥2NRTI 68/534 (13) 1.43 1.98, 2.08 
Other 6/165 (9) 0.99 0.41, 2.41 
Calendar 
year  
<2004 61/460 (13) 1.00 - 
<0.001 - 2004 - <2008 109/692 (16) 1.22 0.87, 1.72 
≥2008 67/774 (9) 0.62 0.43, 0.90 
aOR=adjusted odds ratio; ART=antiretroviral therapy; BMI=body mass index; CI=confidence interval; 
CMV=cytomegalovirus; EFV= efavirenz; NRTI=nucleoside reverse transcriptase inhibitors; 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Flowchart of children included in the analysis 
Note:  ART=antiretroviral therapy; PIR=poor immune response; VS= viral suppression 
Figure 2: Time to immune recovery among children with advance or severe immunosuppression at 

























































Supplementary  Tables 
Table S1: Predictors of Poor immune response at 2 years of viral suppression 




OR 95% CI p-value OR 95% CI p 
Demographics 
Sex 
Female 55/839 (7) 1.01 0.68, 1.51 
0.958 - 
Male 49/755 (6) 1.00 - 
Place of birth 
Country of cohort 60/956 (6) 1.00 - 
0.608 - Abroad  39/587 (7) 1.06 0.70, 1.61 
Unknown 5/51 (10) 1.62 0.62, 4.23 
Year of birth 
<2000 81/840 (10) 1.00 - 
<0.001 - 
≥2000 23/754 (3) 0.29 0.18, 0.47 
Mode of HIV 
infection 
Perinatal 91/1465 1.00 - 
0.092 - 
Other/ Unknown 13/129 1.69 0.92, 3.12 
Region of 
cohort 




Eastern Europe 8/136 (6) 1.31 0.59, 2.94 2.71 1.48, 4.93 
Western/Central 
Europe 
30/498 (6) 1.35  0.80, 2.27 2.03 0.86, 4.82 
Thailand 37/322 (11) 2.73  1.64, 4.52 1.52 0.86, 2.68 
Characteristics at start of ART 
Age (years) 




5 - <10 39/537 (7) 2.92  1.61, 5.29 2.60 1.39, 4.87 
10 - <15 38/392 (10) 4.00 2.20, 7.29 3.95 2.10, 7.45 








Mild 2/159 (1) 1.04 0.17, 6.30 0.95 0.15, 5.84 
Advanced 16/217 (7) 6.50 1.87, 22.63 5.61 1.58, 19.99 
Severe 72/769 (9) 8.44 2.63, 27.02 6.14 1.87, 20.14 
Unknown 11/201 (5) 4.73 1.30, 17.19 4.43 1.20, 16.36 
Viral load 
(copies/mL) 
>100,000 37/645 (6) 1.00 - 
0.550 - ≤100,000 49/679 (7) 1.28  0.82, 1.99 
Unknown 18/270 (7) 1.17 0.66, 2.10 
AIDS 
diagnosis  
Yes 80/1282 (6) 1.25 0.78, 2.01 
0.353 - 
No 24/312 (8) 1.00 - 
Hepatitis B 
co-infection 
Yes 6/44 (14) 2.34 0.97, 5.67 
0.060 
2.39 0.94, 6.11 
0.068 
No/Unknown 98/1550 (6) 1.00 - 1.00 - 
Hepatitis C 
co-infection 
Yes 5/41 (12) 0.90 0.31, 2.59 
0.845 - 
No/Unknown 92/1321 (7) 1.00 - 
Tuberculosis 
disease 
Yes 1/35 (3) 0.42 0.06, 3.07 
0.389 - 
No 103/1559 (7) 1.00 - 
CMV 
coinfection 
Yes 1/29 (3) 0.51 0.07, 3.76 
0.507 - 
No 103/1565 (7) 1.00 - 
BMI-for-age 
z-score 
>0 23/518 (4)  1.00 - 
0.031 - 
-3 to 0 48/543 (9) 2.09  1.25, 3.48 
<-3 2/54 (4) 0.83 0.19, 3.61 
Unknown 31/479 (6) 1.49 0.86, 2.59 
Initial 
regimen 




EFV+≥2NRTI 45/619 (7) 1.47 0.88, 2.45 0.91 0.51, 1.63 
NVP+≥2NRTI 27/457 (6) 1.18 0.67, 2.08 0.89 0.43, 1.84 
Other 8/43 (19) 4.30 1.80, 10.26 5.19 2.02, 13.34 
Calendar 
year  
<2004 30/407 (7) 1.00 - 
0.051 - 
2004 - <2008 48/611 (8) 1.07 0.67, 1.72 
6XSSOHPHQWDOGDWD$SSHQGL[SXEOLVKHGRQOLQHRQO\ &OLFNKHUHWRDFFHVVGRZQORDG6XSSOHPHQWDOGDWD$SSHQGL[SXEOLVKHGRQOLQHRQO\6XSSOHPHQWDU\7DEOHV&/($1GRF[
≥2008 26/576 (5) 0.59 0.35, 1.02 
 
  
 Table S2:  Rates and rate ratios for death/CDC C events between start of viral suppression+1 year and 
end of viral suppression, by immune status at 1 year of viral suppression 
WHO immune stage 





of CDC C 
events 
Rate of 
death/CDC C (95% 
CI) per 100,000PY 



















   None 3 10 232 (123, 366) 
   Mild 0 6 514 (231, 1144) 
Advanced/Severe (PIR) 4 5 1052 (547, 2022) 
   Advanced 0 3 656 (211, 2033) 
   Severe 4 2 1509 (678, 3358) 
ART=antiretroviral therapy; CDC=Centers for Disease Control and Prevention; CI=confidence interval; 
PIR=poor immune response; PY=person-years; RR=rate ratio; VS=viral suppression; WHO=World 
Health Organization 
  
Table S3:  Growth during viral suppression by immune response status 
ART=antiretroviral therapy; BMI=body mass index; IQR=interquartile range; VS=viral suppression 
 
 All cohorts 
Good immune 
response at 1 
year of VS 
(N=1689) 
Poor immune 
response at 1 
year of VS 
(N=237) 
p-value 
n (%) or median (IQR) 
BMI-for-
age z score 
Start of ART 0.0 (-1.0, 0.8) -0.4 (-1.5, 0.5) 0.002 
1 year of VS  0.2 (-0.5, 1.0) 0.0 (-0.7, 0.8) 0.023 
Increase from ART to 1 year of VS 0.2 (-0.3, 0.9) 0.3 (-0.3, 1.1) 0.120 
Severe wasting (≤-3) at start of ART 45 (4) 17 (10) <0.001 
Severe wasting (≤-3) at 1 year of VS 8 (1) 3 (2) 0.139 
Height-for-
age z score 
Start of ART -1.0 (-2.0, -0.1) -1.3 (-2.6, -0.2) 0.005 
1 year of VS  -0.7 (-1.6, 0.1) -1.3 (-2.4, -0.4) <0.001 
Increase from ART to 1 year of VS 0.2 (-0.1, 0.6) 0.1 (-0.2, 0.4) <0.001 
Severe stunting (≤-3) at start of ART 135 (12) 31 (18) 0.021 
Severe stunting (≤-3) at 1 year of VS 79 (6) 26 (13) <0.001 
